News
Patients in UK get early access to GSK’s Jemperli
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a positive opinion, under the Early Access to Medicines Scheme (EAMS), for the use of its anti-PD-1 therapy Jemperli.